Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation

Shuai Wang, Lei Han, Jungsoo Han, Peng Li, Qing Ding, Qing Jun Zhang, Zhi Ping Liu, Chuo Chen, Yonghao Yu

Research output: Contribution to journalArticle

Abstract

PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (PARP1 catalytic inhibition and PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is not well understood. Here we designed a series of small molecule PARP degraders. Treatment with one such compound iRucaparib-AP6 results in highly efficient and specific PARP1 degradation. iRucaparib-AP6 blocks the enzymatic activity of PARP1 in vitro, and PARP1-mediated poly-ADP-ribosylation signaling in intact cells. This strategy mimics PARP1 genetic depletion, which enables the pharmacological decoupling of PARP1 inhibition from PARP1 trapping. Finally, by depleting PARP1, iRucaparib-AP6 protects muscle cells and primary cardiomyocytes from DNA-damage-induced energy crisis and cell death. In summary, these compounds represent ‘non-trapping’ PARP1 degraders that block both the catalytic activity and scaffolding effects of PARP1, providing an ideal approach for the amelioration of the various pathological conditions caused by PARP1 hyperactivation.

Original languageEnglish (US)
Pages (from-to)1223-1231
Number of pages9
JournalNature chemical biology
Volume15
Issue number12
DOIs
StatePublished - Dec 1 2019

Fingerprint

Cardiac Myocytes
Adenosine Diphosphate
Muscle Cells
DNA Damage
Cell Death
Pharmacology
Neoplasms
In Vitro Techniques

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation. / Wang, Shuai; Han, Lei; Han, Jungsoo; Li, Peng; Ding, Qing; Zhang, Qing Jun; Liu, Zhi Ping; Chen, Chuo; Yu, Yonghao.

In: Nature chemical biology, Vol. 15, No. 12, 01.12.2019, p. 1223-1231.

Research output: Contribution to journalArticle

Wang, Shuai ; Han, Lei ; Han, Jungsoo ; Li, Peng ; Ding, Qing ; Zhang, Qing Jun ; Liu, Zhi Ping ; Chen, Chuo ; Yu, Yonghao. / Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation. In: Nature chemical biology. 2019 ; Vol. 15, No. 12. pp. 1223-1231.
@article{a0d4fffd610e45fa842443c983b49477,
title = "Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation",
abstract = "PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (PARP1 catalytic inhibition and PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is not well understood. Here we designed a series of small molecule PARP degraders. Treatment with one such compound iRucaparib-AP6 results in highly efficient and specific PARP1 degradation. iRucaparib-AP6 blocks the enzymatic activity of PARP1 in vitro, and PARP1-mediated poly-ADP-ribosylation signaling in intact cells. This strategy mimics PARP1 genetic depletion, which enables the pharmacological decoupling of PARP1 inhibition from PARP1 trapping. Finally, by depleting PARP1, iRucaparib-AP6 protects muscle cells and primary cardiomyocytes from DNA-damage-induced energy crisis and cell death. In summary, these compounds represent ‘non-trapping’ PARP1 degraders that block both the catalytic activity and scaffolding effects of PARP1, providing an ideal approach for the amelioration of the various pathological conditions caused by PARP1 hyperactivation.",
author = "Shuai Wang and Lei Han and Jungsoo Han and Peng Li and Qing Ding and Zhang, {Qing Jun} and Liu, {Zhi Ping} and Chuo Chen and Yonghao Yu",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41589-019-0379-2",
language = "English (US)",
volume = "15",
pages = "1223--1231",
journal = "Nature Chemical Biology",
issn = "1552-4450",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation

AU - Wang, Shuai

AU - Han, Lei

AU - Han, Jungsoo

AU - Li, Peng

AU - Ding, Qing

AU - Zhang, Qing Jun

AU - Liu, Zhi Ping

AU - Chen, Chuo

AU - Yu, Yonghao

PY - 2019/12/1

Y1 - 2019/12/1

N2 - PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (PARP1 catalytic inhibition and PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is not well understood. Here we designed a series of small molecule PARP degraders. Treatment with one such compound iRucaparib-AP6 results in highly efficient and specific PARP1 degradation. iRucaparib-AP6 blocks the enzymatic activity of PARP1 in vitro, and PARP1-mediated poly-ADP-ribosylation signaling in intact cells. This strategy mimics PARP1 genetic depletion, which enables the pharmacological decoupling of PARP1 inhibition from PARP1 trapping. Finally, by depleting PARP1, iRucaparib-AP6 protects muscle cells and primary cardiomyocytes from DNA-damage-induced energy crisis and cell death. In summary, these compounds represent ‘non-trapping’ PARP1 degraders that block both the catalytic activity and scaffolding effects of PARP1, providing an ideal approach for the amelioration of the various pathological conditions caused by PARP1 hyperactivation.

AB - PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (PARP1 catalytic inhibition and PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is not well understood. Here we designed a series of small molecule PARP degraders. Treatment with one such compound iRucaparib-AP6 results in highly efficient and specific PARP1 degradation. iRucaparib-AP6 blocks the enzymatic activity of PARP1 in vitro, and PARP1-mediated poly-ADP-ribosylation signaling in intact cells. This strategy mimics PARP1 genetic depletion, which enables the pharmacological decoupling of PARP1 inhibition from PARP1 trapping. Finally, by depleting PARP1, iRucaparib-AP6 protects muscle cells and primary cardiomyocytes from DNA-damage-induced energy crisis and cell death. In summary, these compounds represent ‘non-trapping’ PARP1 degraders that block both the catalytic activity and scaffolding effects of PARP1, providing an ideal approach for the amelioration of the various pathological conditions caused by PARP1 hyperactivation.

UR - http://www.scopus.com/inward/record.url?scp=85074659344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074659344&partnerID=8YFLogxK

U2 - 10.1038/s41589-019-0379-2

DO - 10.1038/s41589-019-0379-2

M3 - Article

C2 - 31659317

AN - SCOPUS:85074659344

VL - 15

SP - 1223

EP - 1231

JO - Nature Chemical Biology

JF - Nature Chemical Biology

SN - 1552-4450

IS - 12

ER -